Corline Biomedical AB (OSTO:CLBIO) COGS-to-Revenue : -0.31 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Corline Biomedical AB COGS-to-Revenue?

Corline Biomedical AB's Cost of Goods Sold for the three months ended in Mar. 2024 was kr-1.17 Mil. Its Revenue for the three months ended in Mar. 2024 was kr3.74 Mil.

Corline Biomedical AB's COGS to Revenue for the three months ended in Mar. 2024 was -0.31.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Corline Biomedical AB's Gross Margin % for the three months ended in Mar. 2024 was 131.17%.

Corline Biomedical AB COGS-to-Revenue Historical Data

The historical data trend for Corline Biomedical AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corline Biomedical AB COGS-to-Revenue Chart

Corline Biomedical AB Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

-3.18

-5.72

-1.79

-0.29

0.03

Corline Biomedical AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.14	-0.15	0.10	-0.36	-0.31

Corline Biomedical AB COGS-to-Revenue Calculation

Corline Biomedical AB's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.824	/	23.55
	=	0.03

Corline Biomedical AB's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	-1.165	/	3.738
	=	-0.31

Corline Biomedical AB (OSTO:CLBIO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Corline Biomedical AB's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	-1.165 / 3.738
	=	131.17 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Corline Biomedical AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Corline Biomedical AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Corline Biomedical AB (OSTO:CLBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corline Biomedical AB (OSTO:CLBIO) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lefflersgatan 5, Uppsala, SWE, 754 50

Website

http://www.corline.com

Corline Biomedical AB is involved in developing, manufacturing and marketing heparin-based solutions to improve kidney transplantation, cell therapies, and applications in the field of regenerative medicine.

Corline Biomedical AB (OSTO:CLBIO) Headlines

No Headlines